FDA Brief

Warning letters Drugs

FDA warning letter to

Bhargava Phytolab Private Limited

High riskIssued Dec 18, 2024Posted Dec 31, 2024Center for Drug Evaluation and Research (CDER)

FDA warns Bhargava Phytolab over drug and API current good manufacturing practice (CGMP) violations, including inadequate testing and sterility controls.

What happened

FDA inspected the facility from July 22 to July 26, 2024, and found that the company did not adequately test API batches, relied on supplier certificates of analysis (COAs), and did not validate the API process. It also found a water system with a dead leg that was not continuously circulating and no media fills to validate aseptic filling. FDA placed the firm’s products on Import Alert 66-40 on November 15, 2024.

What FDA found

  1. API batches were not adequately tested for conformance to specifications, and the company relied on supplier certificates of analysis instead of performing adequate testing.

    21 CFR parts 210 and 211
  2. Incoming lots of a component were not adequately tested for harmful impurities; the company relied on vendor COAs and had no plan to qualify the contract lab.

    21 CFR parts 210 and 211
  3. The water system used in manufacturing had a dead leg and was not continuously circulating, and it was not adequately monitored.

    21 CFR 211.100(a)
  4. The company had no media fills to validate its aseptic filling process, so it lacked adequate assurance of sterility.

    21 CFR 211.113(b)

What FDA wants

FDA tells the company to respond in writing within 15 working days with corrective actions and prevention plans, including independent assessments, process and aseptic validation, testing plans, and a risk assessment for affected U.S. lots. FDA also says the company must notify it before resuming U.S. drug manufacturing and recommends a qualified CGMP consultant.

Who should pay attention

  • brands that buy APIs or finished drugs from this firm
  • U.S. drug manufacturers using these APIs
  • companies relying on supplier certificates of analysis

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk